Stocks making the biggest moves midday: T-Mobile, Verizon, AT&T, Crown Castle, Teva & more

Midday moves were sharply mixed: T-Mobile fell 13% and AT&T and Verizon each lost 10% amid heightened competition concerns after SpaceX moved to boost Starlink Mobile, while tower companies rose 6%–12%. Teva gained 6% after FDA approval of its monthly injectable schizophrenia treatment; Humana rose 12% after a key Medicare Advantage contract rating improved, while Alignment Healthcare fell almost 14%. Delta missed third-quarter earnings expectations and cut its full-year outlook, Apple fell nearly 2% after a report that iPhone 18 Pro October orders were cut 15%, and Lumentum gained about 7% after its CEO said some optical products were sold out through 2029.

Analysis

The telecom/tower divergence looks more like a change in perceived competitive risk than proof of immediate earnings substitution. Direct-to-device satellite is most threatening at the edges—coverage gaps and emergency connectivity—not necessarily high-capacity urban service. The sharp carrier repricing may therefore be ahead of near-term cash-flow damage; however, sustained customer churn or lower pricing would make the threat real. Tower landlords are not an automatic hedge: their economics depend on carrier network investment, so a prolonged capex retrenchment could eventually weaken leasing demand.

For managed care, Star Ratings affect economics through contract-level quality bonuses and enrollment, not the headline rating alone. HUM’s reaction may be justified if the improved rating applies to a large, durable membership base; ALHC’s decline warrants checking which contracts lost ratings and how much enrollment is exposed. CMS methodology or appeals could change the outcome.

LITE’s demand signal is bullish but supply-constrained: being unable to serve demand limits near-term revenue conversion, while a long sellout claim from management is not independently verified. Track shipment growth, pricing and capacity plans before extrapolating scarcity into durable margins. Apple’s reported order reductions raise a consumer-demand and supplier-inventory risk, but the report is not confirmation of a broad electronics downturn.

DAL’s fuel-driven outlook cut makes fuel and fare trends the near-term test; a sustained fuel spike can overwhelm modest earnings misses. FCX’s move on gold is a weak fundamental signal for a copper-heavy miner. Teva’s approval and Archer’s analyst rating are catalysts, not proof of commercial uptake or execution. Avient’s CEO change and Park’s results lack enough information here to establish a durable change in fundamentals.

Key Decisions for Investors

• Avoid chasing the telecom selloff. Over days to weeks, monitor satellite service adoption, carrier churn/pricing commentary and partnership announcements; consider a small, defined-risk relative-value position long T or VZ versus short TMUS only if the selloff continues without evidence of worsening operating metrics. Falsify the fade if carriers disclose material subscriber losses or revise service-revenue outlooks downward.
• Treat the tower rally as vulnerable to a second-order capex effect. Do not assume CCI, AMT and SBAC are clean beneficiaries; watch carrier network spending and tower leasing guidance before adding exposure. A decline in carrier capex would challenge the tower-positive thesis.
• For HUM versus ALHC, use the 2027 ratings as a contract-level diligence catalyst, not a broad sector signal. Verify affected membership, bonus exposure and enrollment implications before trading; reassess if CMS revisions or company disclosures materially alter the rating mix.
• Do not chase LITE solely on management’s sellout claim. Track quarterly shipments, capacity additions and order conversion; supply relief or weaker optical demand would undermine the scarcity thesis. For AAPL, watch subsequent production and supplier commentary for confirmation before treating the reported cut as a durable demand break.